Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Aurinia Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Aurinia Pharmaceuticals Inc
Rating: 2.39620825
Author: Trendlyne DVM scores

Turnaround Potential

about

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

15.61 0.14 (0.90%)

128.89% Gain from 52W Low

1.3M

XNAS Volume

XNAS 02 Apr, 2026 5:30 PM (EDT)

Low Financial Strength

33.3 / 100

Affordable Valuation

58.0 / 100

Technically Moderately Bullish

67.0 / 100

Turnaround Potential These stocks have weak financials, buying interest and affordable valuations. Investors should exercise caution View Similar Embed DVM

1Yr Price target upside is 9%

7 analysts

Aurinia Pharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

128.89% Gain from 52W Low

SWOT Analysis

Aurinia Pharma Inc Live Price Chart